

This is an author produced version of a paper published in European Journal of Pharmacology. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the published paper:

Luo G, Jamali R, Cao YX, Edvinsson L, Xu CB.

"Vascular endothelin ET(B) receptor-mediated contraction requires phosphorylation of ERK1/2 proteins."



European Journal of Pharmacology, 2006, Vol: 538, Issue: 1-3,  
pp. 124-31

<http://dx.doi.org/10.1016/j.ejphar.2006.03.057>

Access to the published version may require journal subscription.

Published with permission from: Elsevier

# Vascular endothelin ET<sub>B</sub> receptor-mediated contraction requires phosphorylation of ERK1/2 proteins

Guogang Luo<sup>a, b</sup>, Roya Jamali<sup>b</sup>, Yong-Xiao Cao<sup>c</sup>, Lars Edvinsson<sup>b</sup> and Cang-Bao Xu<sup>b</sup>  

<sup>a</sup>Neurology Department of the First Hospital, Medical College of Xian Jiaotong University, P. R. China

<sup>b</sup>Division of Experimental Vascular Research, Institute of Clinical Science, Lund University, Sweden

<sup>c</sup>Department of Pharmacology, Medical College of Xian Jiaotong University, P. R. China

Received 15 September 2005; revised 23 March 2006; accepted 27 March 2006.  
Available online 4 April 2006.

 Corresponding author. Division of Experimental Vascular Research, Institution

## Abstract

In cardiovascular diseases, endothelin type B (ET<sub>B</sub>) receptors in arterial smooth muscle cells are upregulated. The present study revealed that organ culture of rat mesenteric artery segments enhanced endothelin ET<sub>B</sub> receptor-mediated contraction paralleled with increase in the receptor mRNA and protein expressions. The endothelin ET<sub>B</sub> receptor-mediated contraction was associated with increase in phosphorylation of extracellular regulation kinase 1 and 2 (ERK1/2) proteins and elevated levels of intracellular calcium. The elevation curve of intracellular calcium consisted of two phases: one rapid and one sustained. Inhibition of ERK1/2 phosphorylation by SB386023 or blockage of calcium channels by nifedipine significantly reduced the endothelin ET<sub>B</sub> receptor-mediated contraction ( $P < 0.05$ ) and decreased the sustained phase of intracellular calcium level, but not the rapid phase. Thus, phosphorylation of ERK1/2 proteins and elevation of intracellular calcium level are required for endothelin ET<sub>B</sub> receptor-mediated contraction in rat mesenteric artery.

**Keywords:** Endothelin; ET<sub>B</sub> (endothelin type B); Receptor; ERK1/2 (extracellular regulation kinase 1 and 2); Calcium; Contraction

## 1. Introduction

Endothelin-1 is a strong vasoconstrictor with important role in cardiovascular regulation and atherosclerotic processes. endothelin-1 acts on two G-protein-coupled receptors; endothelin type A (ET<sub>A</sub>) and type B (ET<sub>B</sub>) receptor ([Masaki, 1994](#)). The endothelin ET<sub>A</sub> receptor is located on vascular smooth muscle cells and mediates contraction, whereas the endothelin ET<sub>B</sub> receptor usually is found on the endothelium and induces dilatation via release of nitric oxide (NO) and prostacyclin ([Schiffrin, 1995](#) and [Szok et al., 2001](#)). Contractile endothelin ET<sub>B</sub> receptors are upregulated in vascular smooth muscle cells during organ culture ([Adner et al., 1998a](#) and [Adner et al., 1998b](#)) and in pathological conditions, e.g. in cerebral ischemia ([Stenman et al., 2002](#)) and in coronary ischemia ([Wackenfors et al., 2004](#)).

Increased endothelin ET<sub>B</sub> receptor-mediated contraction has been observed in hypertension, myocardial infarction, congestive heart failure and cerebral ischemia ([Abassi et al., 2004](#), [Roux et al., 1995](#), [Siren et al., 2000](#) and [Alafaci et al., 1990](#)). We have observed that the upregulation of endothelin ET<sub>B</sub> receptors can be mimicked by organ culture of arterial segments ([Moller et al., 2002](#), [Uddman et al., 2003](#) and [Adner et al., 1998a](#)). It is well documented that in fresh mesenteric arteries of rat, there is no contractile response to sarafotoxin 6c, a selective endothelin ET<sub>B</sub> receptor agonist ([Adner et al., 1998a](#)). However, after organ culture of mesenteric artery segments, an upregulation of endothelin ET<sub>B</sub>, but not ET<sub>A</sub> receptor, is induced via a transcriptional mechanism and the de novo expressed endothelin ET<sub>B</sub> receptors mediate strong contraction ([Adner et al., 1998a](#), [Adner et al., 1998b](#) and [Moller et al., 2002](#)). While we have, in detail, studied the transcriptional mechanisms that are involved in the enhanced expression of endothelin ET<sub>B</sub> receptors, there is limited knowledge regarding the intracellular events that take place during contraction via these de novo expressed endothelin ET<sub>B</sub> receptors.

Protein kinase C (PKC), extracellular signal-regulated protein kinase 1/2 (ERK 1/2) and intracellular calcium have been revealed to be involved in endothelin-1-induced contraction ([Kwon et al., 2003](#)). However, the intracellular events that take place during contraction induced via vascular endothelin ET<sub>B</sub> receptors are less known. The present study was designed to examine if phosphorylation of ERK1/2 proteins and increase of intracellular calcium level are required for contraction induced via endothelin ET<sub>B</sub> receptors in rat mesenteric artery.

## 2. Materials and methods

### 2.1. Tissue preparation and organ culture procedure

Sprague-Dawley rats (body weight 250–300g) were anaesthetized with dried ice of CO<sub>2</sub> and killed by decapitation. The superior mesenteric artery (0.5–1mm in diameter)

was removed gently, immersed in cold buffer solution (for composition, see below) and dissected free of adhering tissue under a light microscope. The endothelium was denuded by perfusion of the vessel for 10s with 0.1% Triton X-100 and followed by a physiologic buffer solution. The vessels were then cut into 1-mm-long cylindrical segments, used directly (fresh group) or incubated for 24h at 37°C in humidified 5% CO<sub>2</sub> in air (organ culture group). The segments for organ culture were placed in a 96-well plate, one segment in each well, containing 300µl Dulbecco's modified Eagle's medium (DMEM) supplemented with penicillin (100U/ml) and streptomycin (100µg/ml). The reagent SB386023 (a generous gift from Dr. A. A. Parsons, GSK, UK), a specific ERK1/2 inhibitor ([Uddman et al., 2003](#)), was dissolved into dimethylsulfoxide (DMSO), and SB386023 or DMSO were diluted to needed concentration with the DMEM solution. The protocol was approved by the Ethical Committee of Lund University (M 120-01).

## **2.2. In vitro pharmacology**

Fresh or incubated segments were immersed in temperature-controlled (37°C) tissue baths containing a bicarbonate buffer solution. The solution was continuously aerated with 5% CO<sub>2</sub> in O<sub>2</sub> resulting in a pH of 7.4. Each segment was mounted on two L-shaped prongs, one of which was attached to a Grass FT-03 transducer (Grass Instr., Quincy, USA) connected to a PowerLab (AD Instruments, Hastings, UK) unit for continuous recording of isometric tension ([Adner et al., 1998b](#)). A tension about 2.5mN was applied to each segment and the segments were allowed to stabilize at this tension at least one hour before being exposed to a potassium-rich (60mM) buffer solution with the same composition as the standard solution except that NaCl was replaced by an equimolar concentration of KCl. The potassium-induced contraction was used as a reference for the contractile capacity, and the segments were used only if potassium elicited reproducible responses (i.e. two times of potassium-induced contractions are not different by more than 10%) over 1.0mN.

Concentration–response curves for the vasoconstrictor sarafotoxin 6c were obtained by cumulative administration of the agents. Specific ERK1/2 inhibitor SB386023 was added into the tissue bath 30min before administration of sarafotoxin 6c concentration–response curves. To investigate phosphorylation of ERK1/2 proteins in the arterial segments during sarafotoxin-induced contraction, the segments were removed from the prongs just as sarafotoxin 6c (10<sup>-6</sup>M and 10<sup>-8</sup>M)-induced contraction reached the maximum. They were then stored at –80°C for further analysis of ERK1/2 phosphorylation ([Henriksson et al., 2004](#)).

## **2.3. Assay of phosphorylated ERK1/2**

Smooth muscle isolated from fresh or cultured segments was homogenized in 0.5ml of extraction buffer (BioSource International, Inc. CA, USA) supplied with fresh 1mM phenylmethylsulfonyl fluoride (PMSF) (Sigma, St. Louis, MO, USA) and protease inhibitor cocktail (Sigma) by using the FastPrep® instrument (Q-BIOgene, CA, USA). Measurement of phosphorylated ERK1/2 was performed by using a

PhosphoELISAs assay kit (BioSource International, Inc. CA, USA) following the instruction from the supplier. Briefly, the sample was boiled for 5min to denature proteins. The 100- $\mu$ l sample was added in each pre-coated well and incubated for 2h at room temperature. Removal of the sample by aspiration and wash with working wash buffer (supplied in the kit) and then addition of 100 $\mu$ l of primary antibody for phosphorylated ERK1/2 to each well and incubated at room temperature for 1h. Thereafter, the primary antibody was removed by aspiration, washed away and 100 $\mu$ l of anti-Rabbit IgG–HRP conjugated secondary antibody added to each well and incubated for 30min at room temperature. The second antibody was removed and 100 $\mu$ l of stabilized chromogen was added to each well. The plate was incubation at room temperature for 30min in darkness to develop color. Stop solution 100 $\mu$ l was added to each well to stop the reaction. The plate was read at an absorbance of 450nm. The outcome was normalized by the analysis of total protein (Lowry's method).

#### **2.4. Fura 2 loading and measurement of force development**

Mesenteric artery segments (1 mm) were mounted on two 40- $\mu$ m stainless steel wires connected to a force transducer in the organ bath of a Confocal Wire Myograph, specially designed for obtaining high resolution image of fluorescence dyes (DMT120CW, Danish Myo Technology A/S, Aarhus, Denmark). After mounting, the arteries were equilibrated in PSS at 37°C, pH7.4, for 30min. Mesenteric artery segments were loaded with the fluorescent  $\text{Ca}^{2+}$  indicator dye (Fura 2) by incubation in PSS containing 20 $\mu$ M Fura 2-AM (an acetoxymethyl ester form of Fura 2; Sigma), 0.5% (v/v) DMSO (Sigma), and 0.08% (v/v) pluronic F-127 (Sigma). Pluronic F-127 (non-ionic detergents) has been reported to improve the efficiency when loading with Fura 2-AM ([Roe et al., 1990](#)). The arteries were loaded for 2h at 37°C. After loading with Fura 2, physiological salt solution (PSS) that exchanged NaCl to KCl (KPSS) induced tension development with the same time course as observed before loading. KPSS-induced contraction was followed by rinsing, and the buffer was changed to PSS with nifedipine (Sigma), DMSO, or SB386023. Thereafter, sarafotoxin 6c ( $5 \times 10^{-7}$  M) was added to induce contraction.

#### **2.5. Measurement of $[\text{Ca}^{2+}]_i$**

The myograph was placed on an inverted microscope (Olympus IX70, USA) for measurement of intracellular calcium  $[\text{Ca}^{2+}]_i$ . The arteries were illuminated with 340 and 380nm light from SpectraMASTER (Life Science Resource, USA). During the experiments, fluorescence signals and force signals were captured by charge coupled devices with a camera head (CCD, Life Science Resource, OLYMPUS EUROPE, UK), and saved by a PC computer. Intracellular  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_i$ ) was calculated according to the equation;  $[\text{Ca}^{2+}]_i = K_d \beta [(R - R_{\min}) / (R_{\max} - R)]$ . The dissociation constant,  $K_d$ , of the Fura 2– $\text{Ca}^{2+}$  complex, is 225nM at 37°C ([Grynkiewicz et al., 1985](#)).  $R_{\max}$  and  $R_{\min}$  are the highest and the lowest concentration of calcium that each segment had in the experiments.  $R_{\max}$  was determined in each vessel at the end of the experiment by adding a buffer-solution containing 10mM  $\text{Ca}^{2+}$ .

$R_{\min}$  was determined by incubation with the  $\text{Ca}^{2+}$ -free buffer plus 2mM EGTA and 20 $\mu\text{M}$  ionomycin (Sigma) for 10min. The parameter  $\beta$  is the ratio of emission at 380nm of  $R_{\min}$  to emission at 380nm of  $R_{\max}$  (corrected for background fluorescence signals). The ratio ( $R$ ) was calculated by dividing the emission at 340nm illuminations and emission at 380nm illuminations. Background fluorescence signals were obtained by quenching the calcium-sensitive Fura 2 fluorescence with 20mM  $\text{Mn}^{2+}$  at the end of each experiment ([Jensen et al., 1992](#), [Grynkiewicz et al., 1985](#) and [Roe et al., 1990](#)).

## 2.6. Western blot

After organ culture, whole vessels were collected and placed on ice, homogenized in lysis-buffer with protease and phosphatase inhibitors (10mM Tris pH7.4, 50mM  $\beta$ -glycerophosphate, 100 $\mu\text{M}$   $\text{Na}_3\text{VO}_4$ , 0.5% deoxycholate, 1mM EGTA, 1mM EDTA, 1mM NaF, 20mM  $\text{Na}_4\text{P}_2\text{O}_7$ , 1% Triton X-100, 1mM DTT, 20 $\mu\text{M}$  pepstatin, 20 $\mu\text{M}$  leupeptin, 0.1U/ml aprotinin, 1 nM calyculin and 1mM PMSF). Total protein concentration was determined using a BioRad DC kit (Hercules, CA, USA) and a Genesys 6 spectrophotometer (Thermo, Waltham, MA, USA). Same amount of 45 $\mu\text{g}$  total protein was loaded per lane on a 10% sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) and blotted onto a Hybond PolyVinylidene Fluoride (PVDF) membrane for 30min at 1.5mA/cm<sup>2</sup>. Subsequently the membrane was blocked in 5% non-fat milk for 1h at room temperature and incubated with primary antibody overnight at 4°C and with secondary antibody (Pierce, Rockford, IL, USA) for 1h at room temperature. The membranes were developed using the Supersignal Dura kit (Pierce) and visualized using a Fujifilm LAS-1000 Luminiscent Image Analyzer (Stamford, CT, USA). The endothelin ET<sub>B</sub> antibody (Chemicon, Temecula, CA, USA) was used at 1:1000.

## 2.7. Real-time polymerase chain reaction (real-time PCR)

Smooth muscle isolated from fresh or cultured segments was homogenated in 1ml of the RNApro™ solution (Q-BIOgene) by using a FastPrep® instrument (Q-BIOgene). The total RNA was extracted following a protocol from the FastRNA® Pro kit supplier. Reverse transcription of total RNA to cDNA was carried out using the Gene Amp RT kit (PE Applied Biosystems) in a Perkin-Elmer 2400 PCR machine at 42°C for 30min. The real-time quantitative PCR was performed with the GeneAmp SYBR Green PCR kit (PE Applied Biosystems) in a Perkin-Elmer Real-time PCR machine (PE, GeneAmp 5700 sequence detection system). The system automatically monitors the binding of a fluorescent dye to double-strand DNA by real-time detection of the fluorescence during each cycle of PCR amplification. Specific primers for rat endothelin ET<sub>B</sub> receptor was designed based on gene bank data by using Primer Express 2.0 software (PE Applied Biosystems).

Endothelin ET<sub>B</sub> receptor primers

Forward: 5'-GATACGACAACTTCCGCTCCA-3'

Reverse: 5'-GTCCACGATGAGGACAATGAG-3'

The house keeping gene, glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA continuously expressed to a constant amount in the arterial smooth muscle, was compared with the house keeping gene elongation factor-1 (EF-1) in a pilot study by real-time PCR. GAPDH was used as a reference in this study, but both were equally well constant in the tests.

GAPDH primers

Forward: 5'-GGCCTTCCGTGTTCCCTACC-3'

Reverse: 5'-CGGCATGTCAGATCCACAAC-3'

The PCR reaction was performed in a 50 $\mu$ l volume and started at a temperature of 50°C for 2min, 95°C for 10min and the following 40 PCR cycles with 95°C for 15s and 60°C for 1min. Dissociation curves were run after the real-time PCR to identify the specific PCR products. All primers were designed using the Primer Express 2.0 software (PE Applied Biosystems) and synthesized by TAG Copenhagen A/S (Denmark).

Data were analyzed with the comparative cycle threshold ( $C_T$ ) method. To evaluate the amount of endothelin  $ET_B$  receptor mRNA in a sample, GAPDH mRNA was assessed in the same sample simultaneously. The  $C_T$  values of GAPDH mRNA were used as a reference to quantify the relative amount of endothelin  $ET_B$  receptor mRNA. The relative amount of mRNA was calculated with the  $C_T$  values of endothelin  $ET_B$  receptor mRNA in relation to the  $C_T$  values of GAPDH mRNA in the sample.

## 2.8. Buffer solutions and drugs

Standard buffer solution (mM): NaCl 119, NaHCO<sub>3</sub> 15, KCl 4.6, MgCl 1.2, NaH<sub>2</sub>PO<sub>4</sub> 1.2, CaCl<sub>2</sub> 1.5, and glucose 5.5. Analytical grade chemicals and double distilled water were used for preparing all solutions. Dulbecco's modified Eagle's medium, penicillin and streptomycin were purchased from Gibco BRL (Paisley, Scotland) and HEPES from Sigma. Nifedipine, ionomycin, Fura 2-AM and SB386023 were dissolved in DMSO. Sarafotoxin 6c and endothelin-1 (Auspep, Parkville, Australia) were dissolved in sterile water with bovine serum albumin (0.1% w/v) for in vitro pharmacology, or in 0.9% saline with bovine serum albumin (10% w/v) for intracellular calcium studies. PSS had the following composition (in mM): NaCl 125, NaHCO<sub>3</sub> 5, KCl 5, NaH<sub>2</sub>PO<sub>4</sub> 0.5, MgCl<sub>2</sub>·6H<sub>2</sub>O 2, CaCl<sub>2</sub> 1.8, bovine serum albumin (BSA) 0.05, and glucose 10. The pH was adjusted to 7.4 with NaOH. Solutions used for determination of  $R_{min}$  and  $R_{max}$  contained (in mM):

4-(2-hydroxyethyl)-1-piperazineethane sulphonic acid (HEPES) 5, KCl 125,

MgCl<sub>2</sub>·6H<sub>2</sub>O 1.17 and glucose 5.5, with addition of 2mM EGTA or 10mM CaCl<sub>2</sub>·2H<sub>2</sub>O, respectively and pH was adjusted to 7.4 with KOH.


## 2.9. Calculation and statistics

Data are expressed as mean values±S.E.M. Contractile responses in each segment are expressed as a percentage of the 60mM potassium-induced contraction.  $E_{max}$  represents the maximal contraction induced by an agonist. The pEC<sub>50</sub> value was calculated from the line between the concentrations above and below the midpoint of the concentration–response curve. Student's *t*-test was applied and  $P<0.05$  considered as a significant difference.

## 3. Results

### 3.1. Upregulation of endothelin ET<sub>B</sub> receptors

The selective endothelin ET<sub>B</sub> receptor agonist, sarafotoxin 6c, did not induce any contraction in fresh segments of rat mesenteric artery, while after organ culture of the artery segments for 24h; it induced strong contraction with an  $E_{max}$  of 239±26% and a pEC<sub>50</sub> of 7.98±0.07 (Fig. 1A). This increase of contraction induced via endothelin ET<sub>B</sub> receptors occurred in parallel with a significant increase of the endothelin ET<sub>B</sub> receptor mRNA level in the smooth muscle cells ( $P<0.01$ , Fig. 1B). Western blot using a specific endothelin ET<sub>B</sub> receptor antibody confirmed the receptor upregulation at the protein level (Fig. 1A).








Fig. 1. (A) Effects of sarafotoxin 6c (S6c) on fresh (○) and 24h organ cultured (▲) rat mesenteric artery segments. Each data point was derived from 9 to 10 experiments and represented as percentage of 60mM KCl-induced maximal contraction with mean±S.E.M. Western blot by using the specific antibody against endothelin ET<sub>B</sub> receptors is shown in both fresh (0h) and 24h organ cultured (24h). The Western blot analysis has been repeated 4–5 times and produced a similar result as shown here. (B) Effects of organ culture on the expression of mRNA for endothelin ET<sub>B</sub> receptors. The smooth muscle was isolated from the fresh or organ cultured arteries. The relative amount of mRNA for endothelin ET<sub>B</sub> receptors was quantified by the real-time PCR. Each data point was derived from 4 experiments and presented as mean±S.E.M. \*\**P*<0.01 compared with fresh.

### 3.2. Effect of ERK1/2 inhibitor and calcium channel blocker

SB386023 ( $10^{-5}$ M) or nifedipine ( $10^{-6}$ M) was added 30min before administration of sarafotoxin 6c to induce concentration–response curves in organ cultured artery segments. SB386023 significantly reduced the maximum contraction of sarafotoxin 6c (Fig. 2A). The  $E_{max}$  decreased from  $239\pm 26\%$  ( $n=9$ ) to  $89\pm 13\%$  ( $n=8$ ) ( $P<0.01$ ), while the  $pEC_{50}$  did not show a significant change ( $7.98\pm 0.07$  vs.  $7.89\pm 0.11$ ,  $P>0.05$ ). Nifedipine decreased the maximal contraction induced by sarafotoxin 6c from  $205\pm 27\%$  ( $n=8$ ) to  $106\pm 18\%$  ( $n=11$ ) ( $P<0.01$ ) with no significant change in the  $pEC_{50}$  value ( $8.12\pm 0.02$  vs.  $7.92\pm 0.03$ ,  $P>0.05$ ). Incubation of the artery rings in a combination of SB386023 and nifedipine for 30min further decreased the contraction

to an  $E_{\max}$  of  $41 \pm 6\%$  ( $P < 0.05$ ; Fig. 2B, Table 1).




Fig. 2. (A) Sarafotoxin 6c (S6c)-induced contraction curves in the absence (○) or presence (▲) of SB386023 ( $10^{-5}$  M). SB386023 was added 30min before the administration of sarafotoxin 6c to segments cultured for 24h. DMSO served as control ( $n=9-10$ ). (B) Sarafotoxin 6c (S6c)-induced contraction curves in the absence (○) or presence (▲) of nifedipine ( $10^{-6}$  M) or combination SB386023 ( $10^{-5}$  M) plus nifedipine ( $10^{-6}$  M) (●). The experiments ( $n=8-11$ ) were performed as in (A). Each data point is shown as mean  $\pm$  S.E.M.

Table 1.

Effects of SB386023 or nifedipine or the combination on contraction induced by sarafotoxin 6c via endothelin ET<sub>B</sub> receptors

	<i>N</i>	<b>K<sup>+</sup> mean</b>	<b>Sarafotoxin 6c</b>		
			<i>E</i> <sub>max</sub> (mN)	<i>E</i> <sub>max</sub> (%)	pEC <sub>50</sub>
Fresh	9	2.15±0.35	0	0	0
Organ culture	9	2.58±0.28	4.64±0.54	239±26	7.98±0.07
with SB386023	10	2.84±0.39	3.14±0.33	89±13 <sup>a</sup>	7.89±0.11
with nifedipine	8	2.43±0.31	3.76±0.42	106±18 <sup>b</sup>	7.92±0.03
with SB386023 + nifedipine	8	2.19±0.25	3.83±0.39	41±6	8.26±0.04
with Control (DMSO)	11	2.38±0.27	4.12±0.47	205±27	8.12±0.02

Data are shown as mean±S.E.M. *N* denotes the number of experiments.

<sup>a</sup>*P*<0.01 vs. Control (DMSO).

<sup>b</sup>*P*<0.01 vs. Organ culture.

To further study the inhibitory effect of SB386023, the ERK1/2 pathway inhibitor was added during a steady-state contraction induced by sarafotoxin 6c. Sarafotoxin 6c (10<sup>-8</sup>M) elicited an immediate contraction which reached a stable contraction within 1min and the tone remained stable for more than 10min. Addition of SB386023 (10<sup>-5</sup>M or 10<sup>-4</sup>M) resulted in a time- and concentration-dependent relaxation. The sarafotoxin 6c contraction curves began to decline within 1min, and it took 9min for 10<sup>-5</sup>M SB386023 and 3.5min for 10<sup>-4</sup>M SB386023 to reduce contraction by 50% (Fig. 3A). Nifedipine (10<sup>-6</sup>M) instantly relaxed sarafotoxin 6c-induced contraction to a reduction in the *E*<sub>max</sub> of approximately 50% of the maximal contraction within 1min

(Fig. 3B).





Fig. 3. (A) Time course of the sarafotoxin 6c (S6c)-induced contraction in absence (□) or in the presence of SB386023 (● 10<sup>-5</sup>M and ▼ 10<sup>-4</sup>M) were added when the stable contraction has been achieved. Each data point is shown as mean±S.E.M. (B) Time course of the sarafotoxin 6c-induced contraction in absence (●) or in the presence of nifedipine (10<sup>-6</sup>M) (▼) were added when the stable contraction has been achieved. Each data point is shown as mean±S.E.M.

### 3.3. Intracellular calcium

Sarafotoxin 6c induced a contraction that occurred in parallel with a rise in the intracellular calcium level (Fig. 4A). The increase of intracellular calcium consisted of two phases: one phasic, considered due to calcium released from the sarcoplasmic reticulum (SR), and one tonic considered due to calcium influx of extracellular calcium via calcium channels. The ERK1/2 inhibitor, SB386023 (10<sup>-5</sup>M), significantly decreased the Tonic but not the phasic phase (Fig. 4C). Nifedipine, a specific calcium influx inhibitor, behaved in a similar way; it blocked mainly the

sustained tonic phase of the intracellular calcium level and not the initial phasic phase (Fig. 4B). However, during incubation with SB386023 for 30min, the basic (resting) level of intracellular calcium in the artery segments ( $492\pm 105\text{nM}$ ;  $P<0.05$ ) was significantly higher than in DMSO ( $189\pm 70\text{nM}$ ), a phenomenon not seen with nifedipine ( $108\pm 42\text{nM}$ ) (Fig. 4D).







Fig. 4. Typical intracellular calcium concentration curves induced via endothelin  $ET_B$  receptors by sarafotoxin 6c in the artery segments in absence (A) or presence of nifedepine ( $10^{-6}M$ ) (B) or SB386023 ( $10^{-5}M$ ) (C). Basic (resting) levels of intracellular calcium concentration in the groups are shown in (D). The experiments ( $n=4-5$ ) were performed as in [Fig. 2](#) and in parallel with assessment of intracellular calcium concentration. Data points in (D) are presented as mean $\pm$ S.E.M.

### 3.4. ERK1/2 phosphorylation during force development via endothelin $ET_B$ receptors

In a separated series of experiments, the contraction induced by sarafotoxin 6c ( $10^{-6}M$  or  $10^{-8}M$ ) rapidly reached a stable state of contraction at 2min ( $n=8$ ) ([Fig. 5A](#)). At this time point, the vessel segments were quickly removed from the tissue bath and immediately frozen for examination of the level of phosphorylated ERK1/2 proteins. The results revealed a significant rise in phosphorylated ERK1/2 proteins that occurred in parallel with the contraction ([Fig. 5B](#)).






Fig. 5. Force development via endothelin  $ET_B$  receptors induced by sarafotoxin 6c (S6c) ( $10^{-6}M$  and  $10^{-8}M$ ) (A) and phosphorylation of ERK1/2 proteins (B). Each data point is derived from 8 experiments and shown as mean  $\pm$  S.E.M. \*\*  $P < 0.01$  compared with control (without sarafotoxin 6c).

#### 4. Discussion

We have previously demonstrated that in vascular disease, upregulation of contractile endothelin  $ET_B$  receptor plays an important role ([Wackenfors et al., 2004](#) and [Stenman et al., 2002](#)) and this receptor upregulation can be mimicked by organ culture of arteries ([Adner et al., 1998a](#)). Since this altered receptor phenotype is seen in vascular disease, it is important to understand its dynamics of action, particularly if we are aiming to alleviate vascular sequelae due to receptor upregulation. The present study has for the first time shown that phosphorylation of ERK1/2 proteins and elevation of intracellular calcium levels both are associated with contraction induced via endothelin  $ET_B$  receptors. Activation of the contractile endothelin  $ET_B$  receptor by sarafotoxin 6c-induced contraction that occurred in parallel with an increase in intracellular calcium levels and phosphorylation of ERK1/2 proteins. Inhibition of ERK1/2 phosphorylation or blockage of calcium channel significantly reduced the endothelin  $ET_B$  receptor-mediated contraction. The increase of intracellular calcium induced via endothelin  $ET_B$  consists of two phases: one rapid and one sustained. We have previously shown that isolated arteries respond to high potassium solution with a biphasic contraction that consists of an initial fast partly transient contraction (first phase) and an ensuing more slowly developing contraction (second phase) ([Hogestatt et al., 1983](#) and [Hogestatt and Andersson, 1984](#)). Studies have subsequently shown that this is due to activation of different types of calcium channels; a rapid type and a second type that allows calcium to pass through the smooth muscle membrane at a slower rate ([Hogestatt and Andersson, 1984](#)). The later type is typically sensitive to the dihydropyridine type of calcium entering blocker, e.g. nifedipine. A similar bimodal appearance has been described for the thromboxane  $A_2$  analogue

U46619-induced contraction in porcine coronary artery ([Nobe and Paul, 2001](#)). The transient phase of contraction to U46619 was associated with  $\text{Ca}^{2+}$  release from the sarcoplasmic reticulum and a protein kinase C (PKC)-mediated  $\text{Ca}^{2+}$  release, while in the sustained phase, involves  $\text{Ca}^{2+}$  influx from the extracellular space and Rho-kinase-mediated  $\text{Ca}^{2+}$  sensitization ([Nobe and Paul, 2001](#)). The present study has revealed that the ERK1/2 inhibitor SB386023 ( $10^{-5}\text{M}$ ) and the calcium influx inhibitor, nifedipine, significantly decreased the sustained contraction. Taken together, we have demonstrated that phosphorylation of ERK1/2 proteins and elevation of intracellular calcium levels are required for contraction induced via endothelin  $\text{ET}_B$  receptors in rat mesenteric artery and that both calcium-dependent and -independent mechanisms are involved ([Ganitkevich et al., 2002](#) and [Thorne et al., 2004](#)).

Previously, we have characterized alteration of endothelin receptors during organ culture of rat mesenteric artery ([Adner et al., 1998a](#) and [Adner et al., 1998b](#)). The fresh arterial smooth muscle cells do not express functional endothelin  $\text{ET}_B$  receptors, although endothelin  $\text{ET}_B$  receptor mRNA and protein are present in significant levels ([Fig. 1A](#) and [B](#)). The lack of contractile  $\text{ET}_B$  receptors in fresh arterial segments is a general phenomenon that we have seen in mesenteric, cerebral and coronary arteries in rat and in man ([Moller et al., 2002](#), [Stenman et al., 2002](#) and [Wackenfors et al., 2004](#)). Thus,  $\text{ET}_B$  receptors expressed in fresh are most likely relaxant  $\text{ET}_B$  receptors with effects mediated via NO and prostacyclin ([Schiffrin, 1995](#) and [Szok et al., 2001](#)). However, endothelin  $\text{ET}_B$  receptor-mediated contraction occurs following organ culture ([Moller et al., 2002](#)), in experimental animal models of stroke ([Stenman et al., 2002](#)) or subarachnoid hemorrhage ([Hansen-Schwartz et al., 2003](#)). This up-regulation of endothelin  $\text{ET}_B$  receptors has been further documented in vascular disease in humans, including atherosclerotic arteries ([Dagassan et al., 1996](#) and [Pernow et al., 2000](#)), ischaemic heart disease ([Wackenfors et al., 2004](#)) and in cerebrovascular diseases ([Hansen-Schwartz et al., 2003](#)). The mechanisms responsible for the upregulation of endothelin  $\text{ET}_B$  receptors involves gene transcription and include activation of protein kinase ([Uddman et al., 2002](#)) and mitogen-activated protein kinase (MAPK) pathways consist of ERK1/2 ([Uddman et al., 2003](#)). It has been observed that of MAPK and down stream transcriptional factors regulate the gene expression of G-protein-coupled receptors, such as endothelin  $\text{ET}_B$ , 5-hydroxytryptamine ( $5\text{-HT}$ ) $_{2A}$  and bradykinin  $B_1$  and  $B_2$  receptors in response to extracellular stimuli ([Cao et al., 2005](#), [Zhang et al., 2004](#) and [Zhang et al., 2005](#)). Typically, these events induce a contractile phenotype ([Moller et al., 2002](#)).

On the other hand, MAPK activities have been found to be required for contractions induced by angiotensin II and endothelin-1 ([Ishihata et al., 2002](#) and [Kwon et al., 2003](#)). In the present study, we focused on the role of MAPK and intracellular calcium to understand the process of contraction induced via endothelin  $\text{ET}_B$  receptors in rat mesenteric artery and demonstrated that activation of MAPK ERK1/2 is required for the contraction. This is supported by previous findings that contraction induced via G-protein-coupled receptors 5-HT $_{2A}$  receptors in rat mesenteric artery requires ERK1/2 activities ([Cao et al., 2005](#)). Nifedipine, a selective calcium channel



blocker markedly reduced sarafotoxin 6c-induced contraction. The increase of intracellular calcium induced via endothelin ET<sub>B</sub> receptor activation consists of two phases: one rapid and one sustained. The rapid phase of calcium release induced by agonist via endothelin ET<sub>B</sub> receptors, is supposed to occur via the inositol 1, 4, 5-triphosphate [Ins(1, 4, 5)P<sub>3</sub>]-mediated calcium release from the sarcoplasmic reticulum ([Nobe and Paul, 2001](#)). This was, however, not inhibited by nifedipine or SB386023. In arteries incubated with nifedipine or SB386023, the contraction and the level of intracellular calcium decreased after the rapid phase, while in control segments there was a step-wise increase of intracellular calcium levels with associated contraction. Surprisingly, when we compared the basic (resting) level in the arteries among control (DMSO), nifedipine and SB386023 treated groups, there was a higher basic level of intracellular calcium in the SB386023 treated group than in control. The mechanism behind this is not known, but it has been suggested that intracellular calcium belongs to two cytosolic compartments; contractile and non-contractile compartments ([Abe et al., 1995](#)). The increase in basal level of intracellular calcium induced by the ERK1/2 inhibitor was located in the non-contractile compartment and that is why it was dissociated with the contraction. The same phenomenon has been observed in the guinea pig taenia coli and porcine coronary artery ([Thorne et al., 2001](#) and [Thorne et al., 2004](#)).

In conclusion, the present study has revealed that phosphorylation of ERK1/2 and increments in intracellular calcium levels are required for endothelin ET<sub>B</sub> receptor-mediated contraction in rat mesenteric arteries. Both calcium-dependent and -independent mechanisms are involved.

### **Acknowledgements**

This work is supported by the Swedish Research Council (grand no: 5958), Council for Swedish Medical Tobacco Research (grant no.: 200410) and Swedish Heart–Lung Foundation.

### **References**

- [Abassi et al., 2004](#) Z. Abassi, R. Ramadan, H. Schwartz and A. Hoffman, Therapeutic implications of endothelin antagonists for cardiovascular diseases, *Harefuah* **143** (2004), pp. 47–53.
- [Abe et al., 1995](#) F. Abe, M. Mitsui, H. Karaki and M. Endoh, Calcium compartments in vascular smooth muscle cells as detected by aequorin signal, *Br. J. Pharmacol.* **116** (1995), pp. 3000–3004.

[Adner et al., 1998a](#) M. Adner, G.G. Geary and L. Edvinsson, Appearance of contractile endothelin-B receptors in rat mesenteric arterial segments following organ culture, *Acta Physiol. Scand.* **163** (1998), pp. 121–129.

[Adner et al., 1998b](#) M. Adner, E. Uddman, L.O. Cardell and L. Edvinsson, Regional variation in appearance of vascular contractile endothelin-B receptors following organ culture, *Cardiovasc. Res.* **37** (1998), pp. 254–262.

[Alafaci et al., 1990](#) C. Alafaci, I. Jansen, M.A. Arbab, Y. Shiokawa, N.A. Svendgaard and L. Edvinsson, Enhanced vasoconstrictor effect of endothelin in cerebral arteries from rats with subarachnoid haemorrhage, *Acta Physiol. Scand.* **138** (1990), pp. 317–319.

[Cao et al., 2005](#) Y.X. Cao, L.C. He, C.B. Xu, G.G. Luo and L. Edvinsson, Enhanced transcription of contractile 5-hydroxytryptamine 2A receptors via extracellular signal-regulated kinase 1/2 after organ culture of rat mesenteric artery, *Basic Clin. Pharmacol. Toxicol.* **96** (2005), pp. 282–288.

[Dagassan et al., 1996](#) P.H. Dagassan, V. Breu, M. Clozel, A. Kunzli, P. Vogt, M. Turina, W. Kiowski and J.P. Clozel, Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries, *J. Cardiovasc. Pharmacol.* **27** (1996), pp. 147–153.

[Ganitkevich et al., 2002](#) V. Ganitkevich, V. Hasse and G. Pfitzer, Ca<sup>2+</sup>-dependent and Ca<sup>2+</sup>-independent regulation of smooth muscle contraction, *J. Muscle Res. Cell Motil.* **23** (2002), pp. 47–52.

[Grynkiewicz et al., 1985](#) G. Grynkiewicz, M. Poenie and R.Y. Tsien, A new generation of Ca<sup>2+</sup> indicators with greatly improved fluorescence properties, *J. Biol. Chem.* **260** (1985), pp. 3440–3450.

[Hansen-Schwartz et al., 2003](#) J. Hansen-Schwartz, N.L. Hoel, M. Zhou, C.B. Xu, N.A. Svendgaard and L. Edvinsson, Subarachnoid hemorrhage enhances endothelin receptor expression and function in rat cerebral arteries, *Neurosurgery* **52** (2003), pp. 1188–1194.

[Henriksson et al., 2004](#) M. Henriksson, C.B. Xu and L. Edvinsson, Importance of ERK1/2 in upregulation of endothelin type B receptors in cerebral arteries, *Br. J. Pharmacol.* **142** (2004), pp. 1155–1161.

[Hogestatt and Andersson, 1984](#) E.D. Hogestatt and K.E. Andersson, Mechanisms behind the biphasic contractile response to potassium depolarization in isolated rat cerebral arteries, *J. Pharmacol. Exp. Ther.* **228** (1984), pp. 187–195.

[Hogestatt et al., 1983](#) E.D. Hogestatt, K.E. Andersson and L. Edvinsson, Mechanical properties of rat cerebral arteries as studied by a sensitive device for recording of mechanical activity in isolated small blood vessels, *Acta Physiol. Scand.* **117** (1983), pp. 49–61.

[Ishihata et al., 2002](#) A. Ishihata, K. Tasaki and Y. Katano, Involvement of p44/42 mitogen-activated protein kinases in regulating angiotensin II- and endothelin-1-induced contraction of rat thoracic aorta, *Eur. J. Pharmacol.* **445** (2002), pp. 247–256.

[Jensen et al., 1992](#) P.E. Jensen, M.J. Mulvany and C. Aalkjaer, Endogenous and exogenous agonist-induced changes in the coupling between  $[Ca^{2+}]_i$  and force in rat resistance arteries, *Pflugers Arch.* **420** (1992), pp. 536–543.

[Kwon et al., 2003](#) S. Kwon, W.J. Lee, L.H. Fang, B. Kim and H.Y. Ahn, Mitogen-activated protein kinases partially regulate endothelin-1-induced contractions through a myosin light chain phosphorylation-independent pathway, *J. Vet. Med. Sci.* **65** (2003), pp. 225–230.

[Masaki, 1994](#) T. Masaki, Endothelin in vascular biology, *Ann. N. Y. Acad. Sci.* **714** (1994), pp. 101–108.

[Moller et al., 2002](#) S. Moller, E. Uddman, N. Welsh, L. Edvinsson and M. Adner, Analysis of the time course for organ culture-induced endothelin ET<sub>B</sub> receptor upregulation in rat mesenteric arteries, *Eur. J. Pharmacol.* **454** (2002), pp. 209–215.

[Nobe and Paul, 2001](#) K. Nobe and R.J. Paul, Distinct pathways of Ca(2+) sensitization in porcine coronary artery: effects of Rho-related kinase and protein kinase C inhibition on force and intracellular Ca(2+), *Circ. Res.* **88** (2001), pp. 1283–1290.

[Pernow et al., 2000](#) J. Pernow, F. Bohm, B.L. Johansson, U. Hedin and L. Ryden, Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis, *J. Cardiovasc. Pharmacol.* **36** (2000), pp. S418–S420.

[Roe et al., 1990](#) M.W. Roe, J.J. Lemasters and B. Herman, Assessment of Fura-2 for measurements of cytosolic free calcium, *Cell Calcium* **11** (1990), pp. 63–73.

[Roux et al., 1995](#) S. Roux, B.M. Loffler, G.A. Gray, U. Sprecher, M. Clozel and J.P. Clozel, The role of endothelin in experimental cerebral vasospasm, *Neurosurgery* **37** (1995), pp. 78–85.

[Schiffrin, 1995](#) E.L. Schiffrin, Endothelin: potential role in hypertension and vascular hypertrophy, *Hypertension* **25** (1995), pp. 1135–1143.

[Siren et al., 2000](#) A.L. Siren, F. Knerlich, L. Schilling, H. Kamrowski-Kruck, A. Hahn and H. Ehrenreich, Differential glial and vascular expression of endothelins and their receptors in rat brain after neurotrauma, *Neurochem. Res.* **25** (2000), pp. 957–969.

[Stenman et al., 2002](#) E. Stenman, M. Malmsjo, E. Uddman, G. Guido, T. Wieloch and L. Edvinsson, Cerebral ischemia upregulates vascular endothelin ET(B) receptors in rat, *Stroke* **33** (2002), pp. 2311–2316.

[Szok et al., 2001](#) D. Szok, J. Hansen-Schwartz and L. Edvinsson, In depth pharmacological characterization of endothelin B receptors in the rat middle cerebral artery, *Neurosci. Lett.* **314** (2001), pp. 69–72.

[Thorne et al., 2001](#) G.D. Thorne, S. Shimizu and R.J. Paul, Hypoxic vasodilation in porcine coronary artery is preferentially inhibited by organ culture, *Am. J. Physiol., Cell Physiol.* **281** (2001), pp. 24–32.

[Thorne et al., 2004](#) G.D. Thorne, Y. Ishida and R.J. Paul, Hypoxic vasorelaxation:  $Ca^{2+}$ -dependent and  $Ca^{2+}$ -independent mechanisms, *Cell Calcium* **36** (2004), pp. 201–208.

[Uddman et al., 2002](#) E. Uddman, M. Adner and L. Edvinsson, Protein kinase C inhibitors decrease endothelin ET(B) receptor mRNA expression and contraction during organ culture of rat mesenteric artery, *Eur. J. Pharmacol.* **452** (2002), pp. 215–222.

[Uddman et al., 2003](#) E. Uddman, M. Henriksson, K. Eskesen and L. Edvinsson, Role of mitogen-activated protein kinases in endothelin ET<sub>B</sub> receptor up-regulation after organ culture of rat mesenteric artery, *Eur. J. Pharmacol.* **482** (2003), pp. 39–47.

[Wackenfors et al., 2004](#) A. Wackenfors, M. Emilson, R. Ingemansson, T. Hortobagyi, D. Szok, J. Tajti, L. Vecsei, L. Edvinsson and M. Malmsjo, Ischemic heart disease induces upregulation of endothelin receptor mRNA in human coronary arteries, *Eur. J. Pharmacol.* **484** (2004), pp. 103–109. ,

[Zhang et al., 2004](#) Y. Zhang, M. Adner and L.O. Cardell, Up-regulation of bradykinin receptors in a murine in-vitro model of chronic airway inflammation, *Eur. J. Pharmacol.* **489** (2004), pp. 117–126. [SummaryPlus](#) ,

[Zhang et al., 2005](#) Y. Zhang, M. Adner and L.O. Cardell, Glucocorticoids suppress transcriptional up-regulation of bradykinin receptors in a murine in vitro model of chronic airway inflammation, *Clin. Exp. Allergy* **35** (2005), pp. 531–538.